Results 131 to 140 of about 510,697 (405)

Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN‐DU Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods The international UCAN CAN‐DU study prospectively enrolled patients with JIA across Canada and the Netherlands.
Jelleke B. de Jonge   +102 more
wiley   +1 more source

Evaluation and Management of Sleep Disorders in the Hand Surgery Patient. [PDF]

open access: yes, 2016
Despite posing a significant public health threat, sleep disorders remain poorly understood and often underdiagnosed and mismanaged. Although sleep disorders are seemingly unrelated, hand surgeons should be mindful of these because numerous conditions of
Gaspar, Michael P.   +4 more
core   +2 more sources

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner   +21 more
wiley   +1 more source

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]

open access: yes, 2017
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria   +9 more
core   +2 more sources

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

open access: yesArthritis & Rheumatology, 2019
To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA).
P. Mease   +7 more
semanticscholar   +1 more source

IMMUNOPATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS AND PHARMACOLOGICAL PERSPECTIVES

open access: yesReumatismo, 2011
Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors, though the precise causal agents have not yet been identified. The immune system has a major role in their development
A. Genovese   +4 more
doaj   +1 more source

One year in review: ultrasound in arthritis [PDF]

open access: yes, 2016
Musculoskeletal ultrasound (MSUS) has become a relevant part of rheumatology practice and research because it substantially allows us to optimize management of rheumatic and musculoskeletal diseases. This non-invasive imaging modality is a valuable point-
IAGNOCCO, Annamaria, Naredo, Esperanza
core  

Elevated ACKR2 expression is a common feature of inflammatory arthropathies [PDF]

open access: yes, 2017
Objectives. Chemokines are essential contributors to leucocyte accumulation at sites of inflammatory pathology. Interfering with chemokine or chemokine receptor function therefore represents a plausible therapeutic option.
Baldwin, Helen M.   +6 more
core   +1 more source

FRI0364 PREVALENCE OF THE METABOLIC SYNDROME IN PSORIATIC ARTHRITIS: SYSTEMATIC LITERATURE REVIEW AND RESULTS OF THE CARMA COHORT [PDF]

open access: bronze, 2020
Ana Urruticoechea‐Arana   +6 more
openalex   +1 more source

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy